Jubilant Biosys and Yale University announce collaboration toaccelerate multiple small molecule discovery programs
February 9, 2021 - New Haven, CT. & Bengaluru, India—Today, Jubilant Biosys and Yale University haveannounced a research collaboration for multiple small molecule research programs.
Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale
University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry,
structural biology, in-vitro and in-vivo pharmacology among others.
Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said “Yale is one of thetop-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to supportscientific endeavours of Investigators at Yale to pursue novel target ideas for unmet medical conditions. With
our New Discovery Chemistry Site scheduled to commence operations in 2021, we will further add to ourcapability a new infrastructure to service our partners.”“Our CRO relationships are an integral component in our pursuit of helping Yale’s scientific community
Dtransition their research towards commercialization, and we are pleased to have Jubilant Biosys join ourentrepreneurial ecosystem,” said Bill Wiesler, Director of New Ventures and the Blavatnik Fund forDInnovation at Yale, Office of Cooperative Research.

About Jubilant Biosys Limited
Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company,
has a presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development
D services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services
such as Biology, DMPK, Toxicology as well as Medicinal Chemistry and PR&D and GMP scale-up capabilities
up to phase II. It has integrated discovery expertise with a track record of over 75 programs in multiple
therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS
and expanding into Rare Diseases. In addition, it markets “TrialStat™”, a proprietary and flexible clinical
Dtrial data capture software and has started AI/ML activities in drug discovery under its Digital initiative.
DFor more info: www.jubilantbiosys.com
Media Contact:
Drishti Asthana
bd@jubilantbiosys.com

About the Yale Office of Cooperative Research:
Since its founding in 1982, the Yale Office of Cooperative Research (OCR) has built a significant portfolio ofinventions and patents and has grown into an engine of regional economic development. Its mission is tofacilitate the translation of research from Yale’s labs into products and services that benefit society. OCR isrecognized as a leading force for catalyzing economic growth by identifying, counseling and nurturing
early-stage technologies and guiding the transition into robust companies.
More information is available at https://ocr.yale.edu/
Media Contact:
Michelle McQueen
Yale University, Office of Cooperative Researchmichelle.mcqueen@yale.edu+1 917-370-6016

DAbout Jubilant Pharmova Limited

DJubilant Pharmova is born out of a combination of ‘Pharma’ and ‘Nova’ (New) and Jubilant Pharmova
Limited (formerly Jubilant Life Sciences Limited) will continue to focus on offering products and services
with excellence in research and manufacturing, catering to the unmet health needs at an affordable price.
It is an integrated global pharmaceuticals company having three business segments - Pharmaceuticals,Contract Research and Development Services and Proprietary Novel Drugs.

DPharmaceuticals business through Jubilant Pharma Limited is engaged in manufacturing and supply ofRadiopharmaceuticals with a network of 49 Radiopharmacies in the US, Allergy Therapy Products, Contract
Manufacturing of Sterile Injectables and Non-sterile products, Active Pharmaceutical Ingredients and SolidDosage Formulations through six USFDA approved manufacturing facilities in US, Canada and India.
Contract Research and Development Services business represented by Jubilant Biosys Limited provides

Dinnovation and collaborative research to global pharmaceutical innovators through two world-classDresearch centers in Bengaluru and Noida in India.

Proprietary Novel Drugs business through Jubilant Therapeutics Inc. is an innovative patient-centricbiopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune
disorders.
For more information, please visit: www.jubilantpharmova.com